Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
AK106
/
Akesobio, Sichuan Kelun Pharma
Welcome,
Profile
Billing
Logout
0 Diseases
0 Trials
0 Trials
0 News
|
|||||||||
AK106
/
Akesobio, Sichuan Kelun Pharma
Preclinical, Journal:
AK106-001616, a potent and selective inhibitor of cytosolic phospholipase A2: in vivo efficacy for inflammation, neuropathic pain, and pulmonary fibrosis.
(Pubmed Central) - Jan 1, 2020
Herein, we describe the preclinical pharmacology of AK106-001616. We believe that readers of The Journal of Pharmacology and Experimental Therapeutics will be interested in this manuscript because our data demonstrate that oral AK106-001616 may provide valuable effects for wide indications without attendant gastrointestinal and cardiovascular risks.